A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Common Stock holdings, reducing direct ownership to 41,382 shares post-transaction.

The Motley Fool • Jun 7, 2026

Ligand to Participate in June Investor Conferences

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference.

GlobeNewsWire • May 27, 2026

Saying Goodbye To The XOMA Royalty PFDs

Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain pending litigation. The transaction is expected to close in Q3 2026 and be immediately accretive to LGND earnings per share.

Seeking Alpha • May 25, 2026

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 9, 2026

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.

MarketBeat • May 8, 2026

Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of  56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

GlobeNewsWire • May 7, 2026

Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.

GlobeNewsWire • May 5, 2026

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of XOMA Royalty Corporation (NasdaqGM: XOMA) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of XOMA will receive $39.00 in cash for each share of XOMA that they own. KSF is seeking to determine whether this consideration and the process.

Business Wire • Apr 28, 2026

Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million

Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.

WSJ • Apr 27, 2026

Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million

Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the ​companies said on Monday.

Reuters • Apr 27, 2026